NuVasive - NUVA Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings or view top-rated stocks.

12 brokers have issued twelve-month price targets for NuVasive's stock. Their NUVA share price forecasts range from $53.00 to $83.00. On average, they expect the company's share price to reach $60.91 in the next year. This suggests a possible upside of 39.0% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $52.48 at the beginning of the year. Since then, NUVA stock has decreased by 16.5% and is now trading at $43.81.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our NUVA earnings forecast.

NuVasive, Inc. (NASDAQ:NUVA) announced its earnings results on Wednesday, August, 3rd. The medical device company reported $0.47 earnings per share for the quarter, missing analysts' consensus estimates of $0.55 by $0.08. The medical device company earned $310.45 million during the quarter, compared to the consensus estimate of $305.83 million. NuVasive had a positive trailing twelve-month return on equity of 11.12% and a negative net margin of 3.41%.

NuVasive declared that its Board of Directors has approved a stock buyback plan on Tuesday, November 9th 2021, which allows the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase up to 3.5% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board believes its shares are undervalued.

NuVasive updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of $2.15-$2.45 for the period, compared to the consensus earnings per share estimate of $2.31. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.22 billion.

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $43.81.

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.28 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

The company employs 2,900 workers across the globe.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.